Statement: the primary trial has a shorter time frame than the secondary trial.
Primary_evidence: Outcome Measurement:    Duration of Moderate Neurtopenia Post First Chemotherapy Administration   Number of days In which the patient has had an absolute neutrophil count (ANC) Level < 2.0 x 10^9/L after first cycle of chemotherapy   Time frame: The first of 4, 21 Day Chemotherapy Cycles Results 1:    Arm/Group Title: 80  g/kg/Dose of F-627(TC)   Arm/Group Description: This dose of F-627 given only to subjects that are to have TC chemotherapy.   F-627: subcutaneous injection given 1 per chemotherapy.   Overall Number of Participants Analyzed: 35   Mean (Standard Deviation)   Unit of Measure: days  0.6         (1.26) Results 2:    Arm/Group Title: 240  g/kg/Dose of F-627 (TC)   Arm/Group Description: This dose of F-627 given to subjects receiving TC or TAC chemotherapy.   F-627: subcutaneous injection given 1 per chemotherapy.   Overall Number of Participants Analyzed: 37   Mean (Standard Deviation)   Unit of Measure: days  0.6         (1.01)
Secondary_evidence: Outcome Measurement:    Number of Patients With Congestive Heart Failure (CHF) While on Active Treatment   [Not Specified]   Time frame: 6 months Results 1:    Arm/Group Title: AC/PTL   Arm/Group Description: Standard doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (80 mg/m^2) x 12 with concurrent standard dose trastuzumab (weekly x 12, then repeat 3 weeks for an additional 9 months) plus daily lapatinib (modified to 750 mg during Paclitaxel + Trastuzumab + Lapatinib (PTL) and 1000 mg during trastuzumab + lapatinib (TL)) for a total of 12 months.   Overall Number of Participants Analyzed: 109   Measure Type: Number   Unit of Measure: participants  0